Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review5,7-Dichlorothiokynurenic acid
Discontinued Product
5,7-Dichlorothiokynurenic acid (Cat. No. 0296) has been withdrawn from sale for commercial reasons.
Description: Potent NMDA antagonist, acts glycine site
Chemical Name: 5,7-Dichloro-4-mercaptoquinoline-2-carboxylic acid
Biological Activity for 5,7-Dichlorothiokynurenic acid
NMDA receptor antagonist acting at the glycine site; reported to be more potent than the corresponding kynurenic acid analogue.
Technical Data for 5,7-Dichlorothiokynurenic acid
| M. Wt | 274.12 |
| Storage | Desiccate at -20°C |
| CAS Number | 135025-62-6 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for 5,7-Dichlorothiokynurenic acid
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for 5,7-Dichlorothiokynurenic acid
References are publications that support the biological activity of the product.
Moroni et al (1991) Thiokynurenates: a new group of antagonists of the glycine modulatory site of the NMDA receptor. Eur.J.Pharmacol. 199 227 PMID: 1720099
View Related Products by Target
View Related Products by Product Action
Keywords: 5,7-Dichlorothiokynurenic acid, 5,7-Dichlorothiokynurenic acid supplier, NMDA, Receptors, 0296, Tocris Bioscience
Citations for 5,7-Dichlorothiokynurenic acid
Citations are publications that use Tocris products.
Currently there are no citations for 5,7-Dichlorothiokynurenic acid.
Reviews for 5,7-Dichlorothiokynurenic acid
There are currently no reviews for this product. Be the first to review 5,7-Dichlorothiokynurenic acid and earn rewards!
Have you used 5,7-Dichlorothiokynurenic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Pain Research Product Guide
A collection of over 280 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Alzheimer's Disease PosterNew
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.